Related Experiment Video
Updated: Feb 7, 2026
09:38
Dietary Supplementation of Polyunsaturated Fatty Acids in Caenorhabditis elegans
Published on: November 29, 2013
17.6K
Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure
Raphael Wurm1, Lore Schrutka1, Alexandra Hammer1
1Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
European Journal of Clinical Investigation
|July 14, 2018
Summary
Omega-3 fatty acid (n3-PUFA) supplementation impairs HDL antioxidant function in heart failure patients. This finding may explain inconsistent clinical outcomes associated with n3-PUFA use in cardiac disease.
Area of Science:
- Cardiology
- Nutritional Science
- Biochemistry
Background:
- Clinical outcomes of omega-3-polyunsaturated fatty acids (n3-PUFAs) in cardiac patients are inconsistent.
- The impact of n3-PUFAs on HDL's antioxidant capacity in heart failure (HF) remains unclear.
Purpose of the Study:
- To investigate the effect of oral n3-PUFA supplementation on HDL antioxidant capacity in patients with heart failure.
Main Methods:
- A prospective, randomized, double-blind, placebo-controlled trial involving 40 advanced non-ischemic heart failure patients.
- Participants received 1 g/day or 4 g/day of n3-PUFA, or placebo, for 12 weeks.
- HDL antioxidant function was assessed using the HDL inflammatory index.
Main Results:
- HDL antioxidant function was significantly impaired in n3-PUFA treated groups compared to placebo.
- Impairment was dose-dependent, with the 4 g/day group showing the most significant reduction.
- A significant trend (P=0.018) indicated worsening antioxidant function with increasing n3-PUFA dosage.
Conclusions:
- n3-PUFA supplementation adversely affects HDL's antioxidant function in non-ischemic heart failure patients.
- This provides a potential mechanism for the controversial clinical outcomes observed with n3-PUFA supplementation in cardiac disease.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
975
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
975
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
924
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
924
01:28Overview of Fatty Acid Metabolism
37.0K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.0K
01:22Heart Failure VI: Adjunct Therapies
368
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
01:22Heart Failure Drugs: Diuretics
990
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990